Cristina Crespo

Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA’s De Novo pathway

Mateo Aboy, Cristina Crespo, Ariel Dora Stern · npj Digital Medicine · 2024 · 52 citations · Full text

Law, Biomedical Engineering, Health Technology Assessment +14

After Myriad, what makes a gene patent claim 'markedly different' from nature?

Mateo Aboy, John Liddicoat, Kathleen Liddell et al. · Nature Biotechnology · 2017 · 21 citations · Full text

Life Sciences, Genetics, Intellectual Property Law +11

How does emerging patent case law in the US and Europe affect precision medicine?

Mateo Aboy, Kathleen Liddell, Cristina Crespo et al. · Nature Biotechnology · 2019 · 20 citations · Full text

Law, Health Law, Intellectual Property Law +14

Myriad's impact on gene patents

Mateo Aboy, Kathleen Liddell, John Liddicoat et al. · Nature Biotechnology · 2016 · 19 citations

Life Sciences, Biotechnology, Genetics +6

European patent protection for medical uses of known products and drug repurposing

Mateo Aboy, Kathleen Liddell, Matthew Jordan et al. · Nature Biotechnology · 2022 · 17 citations · Full text

Law, Intellectual Property Law, Pharmacology +16